Related Experiment Videos
Does the CYP3A5*3 polymorphism affect in vivo drug elimination?
1Department of Pharmaceutics, University of Washington, Seattle 98195-7610, USA. thummel@u.washington.edu
Pharmacogenetics
|September 30, 2003
Abstract
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Pharmacokinetic Evaluation of a Cinnamon Product on CYP2A6 Substrate Drugs: Application of a Novel Tool Involving the Nicotine Metabolite Ratio.
Clinical pharmacology and therapeutics·2026
Effect of proinflammatory cytokines on intestinal drug transporters in human enteroid monolayers.
Drug metabolism and disposition: the biological fate of chemicals·2025
Leveraging RNA-seq deconvolution to improve complex in vitro model characterization.
The Journal of biological chemistry·2025
Extending Investigations of miR-126-5p on the Regulation of CYP2A6, the Major Nicotine-Inactivating Enzyme.
Pharmacology research & perspectives·2025
Effectiveness and Safety of Spesolimab in Adolescents and Adults with Generalized Pustular Psoriasis.
Pragmatic and observational research·2026
Preclinical Evaluation of Anti-Acne Topical Creams Containing Psorospermum Febrifugum Stem Bark Extract: Lipase Inhibition, Sebum Regulation, and Dermal Safety.
Clinical, cosmetic and investigational dermatology·2026
Impact of Hydrogel Spacer on Radiation Proctitis After Prostate Cancer Radiation Therapy: A Large-Scale Claims Database Analysis.
Advances in radiation oncology·2026
Discovery of a Potent and Selective KRAS G12D Degrader based on PROTAC Degradation.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026